Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1996 Mar;64(3):775–781. doi: 10.1128/iai.64.3.775-781.1996

Enhanced protection by use of a combination of anticapsule and antilipopolysaccharide monoclonal antibodies against lethal Escherichia coli O18K5 infection of mice.

H Frasa 1, B Benaissa-Trouw 1, L Tavares 1, K van Kessel 1, M Poppelier 1, K Kraaijeveld 1, J Verhoef 1
PMCID: PMC173837  PMID: 8641781

Abstract

To study antibody-mediated protection against Escherichia coli peritonitis in BALB/c mice, monoclonal antibodies (MAbs) were generated against the capsule (K5) and the lipopolysaccharide (O18) of E. coli. Flow cytometric analysis with two selected immunoglobulin M MAbs revealed that bacteria were antigenically heterogeneous. Arbitrarily, three subpopulations in E. coli O18K5 cultures could be distinguished by double immunofluorescence. A subpopulation bound only the anti-K5 MAb, and another subpopulation bound only the anti-O18 MAb. An intermediate subpopulation, however, bound both MAbs. In agreement with this result, combinations of both MAbs enhanced phagocytosis of fluorescein isothiocyanate-labeled bacteria by human polymorphonuclear leukocytes and mouse macrophage J774 cells as well. In protection experiments, combinations of both MAbs, preincubated with 3 50% lethal doses of E. coli O18K5, protected all mice upon intraperitoneal challenge. Relatively high doses of either MAb alone proved to be not fully protective in this infection model. Protection of mice by the combination of MAbs was associated with significantly lower (P < 0.02) tumor necrosis factor levels in serum 90 min after challenge compared with any other treatment group. Similarly, prophylactic administration of MAbs yielded significantly lower (P < 0.01) tumor necrosis factor levels in mice that received the combination of MAbs than in any other treatment group.

Full Text

The Full Text of this article is available as a PDF (238.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bassøe C. F., Laerum O. D., Solberg C. O., Haneberg B. Phagocytosis of bacteria by human leukocytes measured by flow cytometry. Proc Soc Exp Biol Med. 1983 Nov;174(2):182–186. doi: 10.3181/00379727-174-41722. [DOI] [PubMed] [Google Scholar]
  2. Cantinieaux B., Hariga C., Courtoy P., Hupin J., Fondu P. Staphylococcus aureus phagocytosis. A new cytofluorometric method using FITC and paraformaldehyde. J Immunol Methods. 1989 Jul 26;121(2):203–208. doi: 10.1016/0022-1759(89)90161-0. [DOI] [PubMed] [Google Scholar]
  3. Cross A. S., Gemski P., Sadoff J. C., Orskov F., Orskov I. The importance of the K1 capsule in invasive infections caused by Escherichia coli. J Infect Dis. 1984 Feb;149(2):184–193. doi: 10.1093/infdis/149.2.184. [DOI] [PubMed] [Google Scholar]
  4. Cross A. S., Kim K. S., Wright D. C., Sadoff J. C., Gemski P. Role of lipopolysaccharide and capsule in the serum resistance of bacteremic strains of Escherichia coli. J Infect Dis. 1986 Sep;154(3):497–503. doi: 10.1093/infdis/154.3.497. [DOI] [PubMed] [Google Scholar]
  5. Cross A. S., Opal S. M., Palardy J. E., Bodmer M. W., Sadoff J. C. The efficacy of combination immunotherapy in experimental Pseudomonas sepsis. J Infect Dis. 1993 Jan;167(1):112–118. doi: 10.1093/infdis/167.1.112. [DOI] [PubMed] [Google Scholar]
  6. Cross A. S., Opal S. M., Sadoff J. C., Gemski P. Choice of bacteria in animal models of sepsis. Infect Immun. 1993 Jul;61(7):2741–2747. doi: 10.1128/iai.61.7.2741-2747.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cross A. S., Zollinger W., Mandrell R., Gemski P., Sadoff J. Evaluation of immunotherapeutic approaches for the potential treatment of infections caused by K1-positive Escherichia coli. J Infect Dis. 1983 Jan;147(1):68–76. doi: 10.1093/infdis/147.1.68. [DOI] [PubMed] [Google Scholar]
  8. Evans M. E., Pollack M., Hardegen N. J., Koles N. L., Guelde G., Chia J. K. Fluorescence-activated cell sorter analysis of binding by lipopolysaccharide-specific monoclonal antibodies to gram-negative bacteria. J Infect Dis. 1990 Jul;162(1):148–155. doi: 10.1093/infdis/162.1.148. [DOI] [PubMed] [Google Scholar]
  9. Evans M. E., Pollack M., Koles N. L., Hardegen N. J., Panopoulos D. Lipopolysaccharide heterogeneity in Escherichia coli J5 variants: analysis by flow cytometry. J Infect Dis. 1992 Oct;166(4):803–811. doi: 10.1093/infdis/166.4.803. [DOI] [PubMed] [Google Scholar]
  10. Frasa H., Procee J., Torensma R., Verbruggen A., Algra A., Rozenberg-Arska M., Kraaijeveld K., Verhoef J. Escherichia coli in bacteremia: O-acetylated K1 strains appear to be more virulent than non-O-acetylated K1 strains. J Clin Microbiol. 1993 Dec;31(12):3174–3178. doi: 10.1128/jcm.31.12.3174-3178.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gant V. A., Warnes G., Phillips I., Savidge G. F. The application of flow cytometry to the study of bacterial responses to antibiotics. J Med Microbiol. 1993 Aug;39(2):147–154. doi: 10.1099/00222615-39-2-147. [DOI] [PubMed] [Google Scholar]
  12. Gransden W. R., Eykyn S. J., Phillips I., Rowe B. Bacteremia due to Escherichia coli: a study of 861 episodes. Rev Infect Dis. 1990 Nov-Dec;12(6):1008–1018. doi: 10.1093/clinids/12.6.1008. [DOI] [PubMed] [Google Scholar]
  13. Greenman R. L., Schein R. M., Martin M. A., Wenzel R. P., MacIntyre N. R., Emmanuel G., Chmel H., Kohler R. B., McCarthy M., Plouffe J. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA. 1991 Aug 28;266(8):1097–1102. [PubMed] [Google Scholar]
  14. Gupta D. S., Jann B., Jann K. Escherichia coli O18ac antigen: structure of the O-specific polysaccharide moiety. Infect Immun. 1984 Jul;45(1):203–209. doi: 10.1128/iai.45.1.203-209.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jann B., Jann K. Structure and biosynthesis of the capsular antigens of Escherichia coli. Curr Top Microbiol Immunol. 1990;150:19–42. doi: 10.1007/978-3-642-74694-9_2. [DOI] [PubMed] [Google Scholar]
  16. Jann K., Jann B. Capsules of Escherichia coli, expression and biological significance. Can J Microbiol. 1992 Jul;38(7):705–710. doi: 10.1139/m92-116. [DOI] [PubMed] [Google Scholar]
  17. Kim K. S., Kang J. H., Cross A. S., Kaufman B., Zollinger W., Sadoff J. Functional activities of monoclonal antibodies to the O side chain of Escherichia coli lipopolysaccharides in vitro and in vivo. J Infect Dis. 1988 Jan;157(1):47–53. doi: 10.1093/infdis/157.1.47. [DOI] [PubMed] [Google Scholar]
  18. McCabe W. R., Kaijser B., Olling S., Uwaydah M., Hanson L. A. Escherichia coli in bacteremia: K and O antigens and serum sensitivity of strains from adults and neonates. J Infect Dis. 1978 Jul;138(1):33–41. doi: 10.1093/infdis/138.1.33. [DOI] [PubMed] [Google Scholar]
  19. Mitov I. G., Terziiski D. G. Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides. Infection. 1991 Nov-Dec;19(6):383–390. doi: 10.1007/BF01726444. [DOI] [PubMed] [Google Scholar]
  20. Nelson D., Neill W., Poxton I. R. A comparison of immunoblotting, flow cytometry and ELISA to monitor the binding of anti-lipopolysaccharide monoclonal antibodies. J Immunol Methods. 1990 Oct 19;133(2):227–233. doi: 10.1016/0022-1759(90)90363-z. [DOI] [PubMed] [Google Scholar]
  21. Pelkonen S., Pluschke G. Use of hybridoma immunoglobulin switch variants in the analysis of the protective properties of anti-lipopolysaccharide antibodies in Escherichia coli K1 infection. Immunology. 1989 Oct;68(2):260–264. [PMC free article] [PubMed] [Google Scholar]
  22. Phillips A. P., Martin K. L. Limitations of flow cytometry for the specific detection of bacteria in mixed populations. J Immunol Methods. 1988 Jan 21;106(1):109–117. doi: 10.1016/0022-1759(88)90278-5. [DOI] [PubMed] [Google Scholar]
  23. Pluschke G., Achtman M. Antibodies to O-antigen of lipopolysaccharide are protective against neonatal infection with Escherichia coli K1. Infect Immun. 1985 Aug;49(2):365–370. doi: 10.1128/iai.49.2.365-370.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Pluschke G., Mayden J., Achtman M., Levine R. P. Role of the capsule and the O antigen in resistance of O18:K1 Escherichia coli to complement-mediated killing. Infect Immun. 1983 Dec;42(3):907–913. doi: 10.1128/iai.42.3.907-913.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Raff H. V., Bradley C., Brady W., Donaldson K., Lipsich L., Maloney G., Shuford W., Walls M., Ward P., Wolff E. Comparison of functional activities between IgG1 and IgM class-switched human monoclonal antibodies reactive with group B streptococci or Escherichia coli K1. J Infect Dis. 1991 Feb;163(2):346–354. doi: 10.1093/infdis/163.2.346. [DOI] [PubMed] [Google Scholar]
  26. Ralph P., Nakoinz I. Phagocytosis and cytolysis by a macrophage tumour and its cloned cell line. Nature. 1975 Oct 2;257(5525):393–394. doi: 10.1038/257393a0. [DOI] [PubMed] [Google Scholar]
  27. Schiff D. E., Wass C. A., Cryz S. J., Jr, Cross A. S., Kim K. S. Estimation of protective levels of anti-O-specific lipopolysaccharide immunoglobulin G antibody against experimental Escherichia coli infection. Infect Immun. 1993 Mar;61(3):975–980. doi: 10.1128/iai.61.3.975-980.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sjursen H., Bjerknes R., Halstensen A., Naess A., Sørnes S., Solberg C. O. Flow cytometric assay for the measurement of serum opsonins to Neisseria meningitidis serogroup B, serotype 15. J Immunol Methods. 1989 Jan 17;116(2):235–243. doi: 10.1016/0022-1759(89)90209-3. [DOI] [PubMed] [Google Scholar]
  29. Tarleton R. L., Beyer A. M. Medium-scale production and purification of monoclonal antibodies in protein-free medium. Biotechniques. 1991 Nov;11(5):590–593. [PubMed] [Google Scholar]
  30. Torensma R., Visser M. J., Aarsman C. J., Poppelier M. J., van Beurden R., Fluit A. C., Verhoef J. Monoclonal antibodies that detect live salmonellae. Appl Environ Microbiol. 1992 Dec;58(12):3868–3872. doi: 10.1128/aem.58.12.3868-3872.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Vermeulen C., Cross A., Byrne W. R., Zollinger W. Quantitative relationship between capsular content and killing of K1-encapsulated Escherichia coli. Infect Immun. 1988 Oct;56(10):2723–2730. doi: 10.1128/iai.56.10.2723-2730.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Wenzel R. P., Andriole V. T., Bartlett J. G., Batt M. D., Bullock W. E., Cobbs C. G., Light B., Martin M. A., Sanford J., Sande M. A. Antiendotoxin monoclonal antibodies for gram-negative sepsis: guidelines from the IDSA. Clin Infect Dis. 1992 Apr;14(4):973–976. doi: 10.1093/clinids/14.4.973. [DOI] [PubMed] [Google Scholar]
  33. Wenzel R. P. The mortality of hospital-acquired bloodstream infections: need for a new vital statistic? Int J Epidemiol. 1988 Mar;17(1):225–227. doi: 10.1093/ije/17.1.225. [DOI] [PubMed] [Google Scholar]
  34. Ziegler E. J., Fisher C. J., Jr, Sprung C. L., Straube R. C., Sadoff J. C., Foulke G. E., Wortel C. H., Fink M. P., Dellinger R. P., Teng N. N. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med. 1991 Feb 14;324(7):429–436. doi: 10.1056/NEJM199102143240701. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES